Why Is Psoriasis Player Ventyx Biosciences Stock Trading Lower Today?

Grand News Network | November 7, 2023

Ventyx Biosciences Inc (NASDAQ: VTYX) released results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis.

The Phase 2 SERENITY trial of VTX958 was a 16-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of four oral doses of VTX958 (50 mg BID, 300 mg QD, 225 mg BID, and 300 mg BID). 

The primary endpoint was the proportion of participants achieving a 75% ...

Full story available on Benzinga.com

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner